PTCT
NASDAQ
US
PTC Therapeutics, Inc. - Common Stock
$67.77
▼ $-0.98
(-1.43%)
Vol 483K
9
Quality Score
ok
Deep Check
1/5
fail
Rev ✓
NI ✗
>IPO ✗
Mkt Cap
$6.1B
P/E
8.1
ROE
-351.9%
Margin
42.3%
D/E
84892.86
Beta
0.47
52W
$36–$88
Wall Street Consensus
21 analysts · Apr 20264
Strong Buy
10
Buy
6
Hold
1
Sell
0
Strong Sell
66.7%
Buy Rating
Price Chart
Similar Stocks
RYTM
Rhythm Pharmaceuticals Inc
$7.1B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
ERAS
Erasca Inc
$1.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.04 | $-1.67 | $-1.71 |
| Sep 2025 | $-1.40 | $0.20 | +$1.60 |
| Jun 2025 | $-1.08 | $-0.83 | +$0.25 |
| Mar 2025 | $-0.22 | $10.04 | +$10.26 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -351.9% | -351.9% | -351.9% | -351.9% | -351.9% |
| P/E (TTM) | 6.15 | 6.26 | 7.75 | 8.62 | 8.38 | 8.11 |
| Net Margin | -36.2% | 35.6% | 35.6% | 35.6% | 42.2% | 42.2% |
| Gross Margin | 93.6% | 97.1% | 97.1% | 97.1% | 96.8% | 96.8% |
| D/E Ratio | — | 84892.86 | 84892.86 | 84892.86 | 84892.86 | 84892.86 |
| Current Ratio | 3.62 | 3.62 | 3.62 | 3.62 | 2.32 | 2.32 |
Key Ratios
ROA (TTM)
31.2%
P/S (TTM)
3.43
P/B
1877.3
EPS (TTM)
$8.53
CF/Share
$-6.03
Rev Growth 3Y
+14.4%
52W High
$87.50
52W Low
$35.95
$35.95
52-Week Range
$87.50
How does PTCT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
PTCT valuation vs Biotechnology peers
P/E ratio
8.1
▼
57%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.4
▼
73%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1877.3
▲
76212%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
PTCT profitability vs Biotechnology peers
ROE
-351.9%
▼
423%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
42.3%
▲
115%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
96.8%
▲
23%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
31.2%
▲
167%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
PTCT financial health vs Biotechnology peers
D/E ratio
84892.9
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.3
▼
48%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
51%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
PTCT fundamentals radar
PTCT
Peer median
Industry
PTCT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
PTCT vs peers: key metrics
Related Signals
Latest AI Opinion
Grok
SKIP
Price action shows a steady decline from the November 2025 peak of around $80 to the current $64.67, with recent weeks trading sideways to lower between $66-70 without clear reversal signals or increasing volume on up days, making this not …
Mar 24, 2026Latest News
No related news yet